

1 **Antecubital Venous Endothelial ETB Receptor Protein Expression is Preserved**
2 **with Aging in Men**

3

4 Saumya Tummala^{1,2}, Andrew V. Kuczmarski¹, Angelica R. Del Vecchio¹, Allyson I. Schwab¹,
5 David G. Edwards¹, and Megan M. Wenner¹

6 ¹ Department of Kinesiology & Applied Physiology, University of Delaware, Newark DE

7 ² Department of Medical & Molecular Sciences, University of Delaware, Newark DE

8

9

10 **Key words:** Endothelin-1, Endothelial Function, Flow-mediated Dilation, Aging

11

12 **Running Title:** ET_BR expression in men

13

14 **Corresponding Author:** Megan M. Wenner, PhD

15 Associate Professor

16 Department of Kinesiology & Applied Physiology

17 University of Delaware

18 Newark, DE, 19713

19 mwenner@udel.edu

20

21

22

23

24 **ABSTRACT**

25 Changes in endothelial function precede the development of cardiovascular disease (CVD). We
26 have previously shown that age-related declines in endothelial function in women are due in
27 part to a reduction in endothelial cell endothelin-B receptor (ET_BR) protein expression. However,
28 it is not known if ET_BR protein expression changes with aging in men. The purpose of this study
29 was to test the hypothesis that ET_BR protein expression is attenuated in older men (OM)
30 compared to younger men (YM). Primary endothelial cells were harvested from the antecubital
31 vein of 14 OM (60±6 yrs; 26±3 kg/m²) and 17 YM (24±5 yrs; 24±2 kg/m²). Cells were stained
32 with 4',6-diamidino-2-phenylindole, vascular endothelial cadherin, and ET_BR. Images were
33 quantified using immunocytochemistry. Endothelial function was assessed using brachial artery
34 flow-mediated dilation (FMD). Systolic BP was similar (OM: 123±11 vs. YM: 122±10 mmHg)
35 whereas diastolic BP was higher in OM (OM: 77±7 vs. YM: 70±6 mmHg; *P*<0.01). Total
36 testosterone was lower in OM (OM: 6.28±4.21 vs. YM: 9.10 ±2.68ng/mL; *P*=0.03). As expected,
37 FMD was lower in OM (OM: 3.85±1.51 vs. YM: 6.40 ±2.68%; *P*<0.01). However, ET_BR protein
38 expression was similar between OM and YM (OM: 0.39±0.17 vs. YM: 0.42±0.17 AU; *P*=0.66).
39 These data suggest that ET_BR protein expression is not altered with age in men. These findings
40 are in contrast to our previous data in women, and further support sex differences in the
41 endothelin system.

42

43 **New & Noteworthy**

44 Our laboratory has previously shown that age-related declines in endothelial function are
45 associated with a reduction in endothelial cell ET_BR protein expression in women. However, it is
46 unclear if endothelial cell ET_BR protein expression is reduced with aging in men. This study
47 demonstrates that endothelial cell ET_BR protein expression is preserved with aging in men, and
48 provides additional evidence for sex differences in the endothelin system.

49

50

51 INTRODUCTION

52 Cardiovascular disease (CVD) is the leading cause for morbidity and mortality in men
53 and women (25). Aging is a primary risk factor for CVD. One mechanism linking the age-related
54 increase in CVD is impaired endothelial function (11). Endothelial cells produce and release
55 several vasoactive substances to regulate vasodilation and vasoconstriction and maintain
56 vascular health. Declines in endothelial function have been documented with aging in both men
57 and women and precede the development of CVD. However, the molecular mechanisms
58 contributing to reductions in endothelial function with aging are not fully understood.

59 Endothelin-1 (ET-1) is a potent vasoconstrictor that is mainly secreted by endothelial
60 cells. ET-1 acts through two receptors: endothelin A receptor (ET_AR) and endothelin B receptor
61 (ET_BR). Both ET_AR and ET_BR are found on vascular smooth muscle cells and induce
62 vasoconstriction (9), however, ET_BR are also located on endothelial cells and mediate
63 vasodilation (6). The ET-1 system is over-active with aging in men. For example, plasma ET-1
64 concentration is greater in older men compared to younger men (12), and cellular protein
65 expression of ET-1 in endothelial cells is also greater in older compared to younger men (3).
66 This higher protein expression of ET-1 in endothelial cells correlated with lower flow-mediated
67 dilation (FMD) – a common measure of endothelial function – suggesting the ET system is one
68 mechanism contributing to age-related declines in endothelial function (3, 19). Concomitant with
69 this heightened ET-1 activity is greater ET-1 vasoconstrictor tone mediated primarily by the
70 ET_AR, which contributes in part to the age-related reduction in endothelium dependent dilation
71 in older men (22, 26). Our laboratory has previously shown that age-related reductions in
72 endothelial function are associated with a reduced protein expression of ET_BR on endothelial
73 cells in women (8), however this has not yet been examined in men.

74 With this background in mind, the purpose of the study was to assess endothelial cell
75 protein expression of ET_BR in young and older men. We hypothesized that ET_BR protein

76 expression would be lower in older men compared to younger men, and that ET_BR protein
77 expression would be positively correlated with FMD.

78

79 **METHODS**

80 All experimental protocols were approved by the University of Delaware Institutional
81 Review Board, and the study conformed to the standards outlined in the Declaration of Helsinki.
82 Verbal and written consent was acquired voluntarily from all men before participation. All men
83 completed a standard medical history questionnaire to rule out prior history of disease; men
84 were excluded if there was a previous history of cardiovascular, metabolic, neurologic, or
85 endocrine disease. Height, body mass, and resting blood pressure (BP) were measured in all
86 men. Hypertensive and obese men were excluded, as well as anyone using tobacco products
87 within the past 6 months. Eight of the 14 OM reported engaging in regular exercise, whereas 14
88 of the 17 YM reported regular exercise. Three YM reported using over the counter (OTC) multi-
89 vitamins and 1 YM reported using seasonal allergy medication. Three OM reported using OTC
90 multi-vitamins, 2 using either fish oil, vitamin C, or magnesium; 4 using vitamin D, 1 using
91 melatonin, and 1 using Nexium. All participants were instructed to refrain from OTC
92 supplements for 72 hours prior to the experimental protocol (below). A fasting blood sample was
93 obtained in a subset of men (13 OM and 8 YM), which was analyzed for cholesterol and blood
94 glucose by LabCorp.

95

96 Experimental Protocol

97 Men reported to the laboratory after refraining from exercise for 24 h, alcohol and
98 caffeine for 12 h, and food for at least 4 h. All subjects laid supine for ~ 20 minutes before
99 measurements were taken. An 18-gauge catheter was placed into an antecubital vein to obtain
100 a blood sample and harvest endothelial cells. Approximately 30 minutes later, endothelial
101 function was assessed via FMD in accordance with currently published guidelines (24). Briefly,

102 longitudinal images of the brachial artery were acquired via ultrasound (GE Logiq e, Healthcare,
103 Wauwatosa, WI) as previously described by our laboratory (8). Images were analyzed offline
104 using automated edge-detection commercial software (QUIPU). Images were not analyzable in
105 1 OM and 3 YM due to movement or inability to maintain a clear vessel throughout the protocol.

106

107 Endothelial Cell Collection and Analysis

108 Endothelial cells were collected using a J-wire that was threaded through an 18-gauge
109 catheter and advanced 2-4 cm into the antecubital vein as previously described (8). The wires
110 were cut and placed into a dissociation buffer (phosphate buffered saline, (PBS), 100ug/mL
111 heparin, 2mMEDTA, and 0.5% BSA) in order to remove the cells from the J-wire, then
112 centrifuged. Cells were then lysed using a red blood cell lysis buffer and centrifuged, isolating
113 the primary endothelial cells. The cells were then fixed in 4% paraformaldehyde and washed in
114 PBS. The endothelial cells were pipetted onto poly-l-lysine coated coverslips, dried at 50°C, and
115 stored at -80°C until staining as previously described (8).

116 Prior to staining, coverslips were randomized so that the technician performing the
117 staining, imaging, and analysis (ST) was blinded to participant ID and group (OM vs YM). The
118 cells were washed and rehydrated with PBS (8). A blocking solution made of cold-water fish
119 skin (2%, Cat. No. G7765, Sigma-Aldrich) and normal donkey serum (5%, Cat. No. D9663,
120 Sigma-Aldrich) was applied (8). Afterwards, the cells were incubated with primary antibodies
121 overnight at 4°C (8). The primary protein of interest was stained using the antibody for the
122 ETBR (1:250, Cat. No. NBP1-30599, RRID:AB_10003663; Novus) as previously described (8).
123 Vascular endothelial cadherin (VE Cad; 1:100, Cat. No. 14-1449-82, RRID AB_467495, Thermo
124 Fisher Scientific) was utilized to identify endothelial cells. The next day, the cells were washed
125 with PBS and incubated with Alexa-fluor conjugated secondary antibodies at 1:1000 dilution for
126 1 hour at 22°C (donkey anti-mouse IgG, Alexa Fluor 594, Cat. No. A-21203, RRID AB_2535789,
127 and donkey anti-rabbit IgG, Alexa Fluor 488 Cat. No. A-21206, RRID AB_2535792; Thermo

128 Fisher Scientific). The cells were washed again and incubated with 4',6-diamidino-2-
129 phenylindole (DAPI; NucBlue, Cat. No. R37606; Thermo Fisher Scientific) to identify the nucleus
130 of the cells. The coverslips were mounted onto glass slides using ProLong Diamond (Cat. No.
131 P36966; Thermo Fisher Scientific) and set aside to harden at 22°C for at least 24 h.

132 Cells were imaged with a ZEISS Axio Imager A2 using a 40x objective lens and HXP
133 120V light source with an AxioCam MRm camera (Zeiss, Oberkichen, Germany) as previously
134 described (8). Laser intensity and exposure time were kept consistent during imaging.
135 Fluorescence intensity of 30 cells were measured per participant and reported as an average
136 intensity, consistent with prior papers in the literature (3, 8, 16). Adequate cell collection was not
137 obtained in two YM and two OM. Human umbilical vein endothelial cells (HUVECs) were stained
138 with the primary antibody to serve as a positive control. To determine any nonspecific binding,
139 HUVECs were also stained with the secondary antibody only, which also served as a negative
140 control. ET_BR protein expression from the primary endothelial cells were normalized to ET_BR
141 protein expression in HUVECs to account for any variability during staining sessions, consistent
142 with the literature (3, 8, 16), and reported as a ratio of ET_BR/HUVEC in arbitrary units (AU).

143

144 Blood sample Analysis

145 A serum blood sample was collected in the morning of the study visit. After
146 centrifugation, serum was stored at -80°C until analyzed. Total testosterone was measured in
147 duplicate using an enzyme-linked immunoassay purchased from Crystal Chem using a BioTek
148 Synergy 2 Multi-Detection Microplate Reader.

149

150 Statistical Analyses

151 Baseline characteristics, ET_BR protein expression, and FMD were compared using a
152 two-tailed, unpaired t-test between the older and younger men. Pearson's correlations were
153 performed to examine the relation between ET_BR protein expression, FMD, and testosterone, as

154 well as cholesterol and blood glucose in the subset of participants on whom we had screening
155 blood samples. All results are reported as mean±SD.

156

157 **RESULTS**

158 Participant characteristics are shown in Table 1. By design, OM were significantly older
159 than YM ($P < 0.001$). Total cholesterol and LDL cholesterol were higher in OM than YM ($P <$
160 0.001), as well as HDL cholesterol ($P = 0.05$). Plasma glucose was also greater in OM
161 compared to YM ($P < 0.01$). Additionally, BMI tended to be higher in OM compared to YM ($P =$
162 0.07). Systolic BP was similar between groups ($P = 0.69$), however diastolic BP was higher in
163 OM ($P < 0.01$). Total testosterone was lower in OM ($n = 13$) compared to YM ($n = 17$; $P = 0.03$).

164 As expected, OM ($n = 13$) had lower FMD compared to YM ($n = 14$; $P < 0.01$), indicating
165 age-related declines in endothelial function (Figure 1A). However, as shown in Figure 1B, ET_BR
166 protein expression was not different between OM ($n = 12$, 0.39 ± 0.17) and YM ($n = 15$, 0.42 ± 0.17 ;
167 $P = 0.66$). There was a trend towards a negative correlation between ET_BR protein expression
168 and FMD (Figure 1C). ET_BR protein expression was negatively correlated with plasma glucose
169 ($r = 0.49$; $P = 0.04$). ET_BR protein expression was not correlated with BMI, exercise frequency, any
170 measures of cholesterol, or total testosterone (all $P = \text{NS}$).

171

172 **DISCUSSION**

173 Endothelial function declines with aging and precedes the development of CVD.
174 Numerous studies have demonstrated that endothelial function is reduced in older compared to
175 younger individuals utilizing the highly reproducible, non-invasive technique of FMD (20).
176 However, the molecular mechanisms are not fully understood and differ based on sex. The
177 primary finding of the current study is that although FMD is lower in older men compared to
178 younger men, ET_BR protein expression is not different between groups. This is in contrast to
179 previous data from our laboratory in women, where we demonstrated decreased protein

180 expression of ET_BR in postmenopausal women compared to young women (8). These findings
181 provide further support for sex differences in the regulation of the endothelin system.

182 Endothelin is a primary mechanism contributing to declines in endothelial function with
183 aging. For example, ET-1 vasoconstriction was greater in older compared to younger men, and
184 blockade of the ET_AR enhanced acetylcholine-mediated vasodilation (27). In addition, protein
185 expression of ET-1 in endothelial cells was greater in older compared to younger men (3).
186 Taken together, these data suggest that heightened ET-1 activity and vasoconstriction via the
187 ET_AR are a primary pathway contributing to age-related declines in endothelial function in men.
188 The current data add to our understanding by showing that the protein expression of ET_BR on
189 endothelial cells is not different with aging in men. Furthermore, ET_BR protein expression was
190 not correlated with endothelial function in men, although there was a trend towards a negative
191 correlation between ET_BR protein expression on endothelial cells and FMD. It is unclear why
192 greater ET_BR protein expression was associated with lower FMD, but could be a compensatory
193 mechanism in response to greater ET-1 protein expression and ET_AR mediated
194 vasoconstriction.

195 Aerobic exercise is known to attenuate ET_AR vasoconstrictor activity, and is one
196 mechanism whereby exercise improves endothelial function in men (26, 27). However, the
197 effect of exercise on ET_BR expression or function has not been extensively studied. In the
198 current study, exercise frequency (days per week) was self-reported as part of our general
199 medical history form, and included both sedentary and active young and older men. While we
200 did not observe an association between self-reported exercise frequency and FMD or ET_BR
201 protein expression, only 30% of our sample was sedentary; future studies that are adequately
202 powered to address the impact of exercise on ET_BR expression and function utilizing
203 quantitative metrics of exercise (such as VO₂max) are needed in both men and women.

204 The findings of the current study of preserved ET_BR protein expression with aging in
205 men are in contrast to previous data in women, where ET_BR protein expression was lower in

206 postmenopausal compared to young women (8). Moreover, ET_BR protein expression in women
207 was positively correlated with FMD, suggesting that a decline in ET_BR protein expression may
208 contribute in part to the declines in endothelial function in women after menopause. Women
209 generally have a greater proportion of ET_BR compared to men (4), and therefore this receptor
210 may have a greater influence on vascular health in women, whereas men have a greater
211 reliance on ET_AR (21). It is interesting to note that when compared to our previous publication
212 (8), YW have higher ET_BR compared to younger men, but this sex difference is no longer
213 apparent in older adults (Fig 2). Therefore, our data further support sex differences in the ET-1
214 system and suggest ET_BR regulation of vascular control is a female-specific mechanism.

215 As men age, reductions in endothelial function may be due to decreasing concentrations
216 of testosterone. Babcock et al. demonstrated that decreased FMD in middle aged/older men
217 compared to younger men were largely driven by testosterone concentration (2). Middle
218 aged/older men with lower testosterone had decreased FMD compared to men of the same age
219 with normal testosterone, and there was a moderate positive correlation between testosterone
220 concentration and FMD. In our study, older men had lower testosterone compared to younger
221 men, but we did not observe a correlation between testosterone and FMD. One reason for the
222 differences between our study and Babcock et al. may be related to sample size, as they tested
223 58 men whereas our sample size was not as robust. However, on an exploratory basis, we
224 performed a median split of testosterone concentration in our older men (“high T”, n=6,
225 9.37±4.41 vs. “low T”, n=7, 3.62±1.19 mg/dL). Older men with higher testosterone had greater
226 FMD compared to older men with lower testosterone (5.10±1.02 vs. 3.23±1.24 %; P=0.02),
227 which is similar to Babcock et al. and suggests that testosterone may be a mediating factor in
228 vascular aging in men.

229 Changes in testosterone concentration can also impact the ET-1 system. For example,
230 testosterone treatment increased ET-1 expression in endothelial cells (15). In porcine coronary
231 arteries, vasoconstrictor responses to ET1 are augmented when treated with testosterone (23).

232 These studies suggest that high concentration of testosterone may augment ET-1 production
233 and vasoconstrictor activity. However, other models of hypoandrogenism also indicate that low
234 testosterone negatively effects ET-1. For example, orchidectomy in animal models resulted in
235 increased gene expression of ET-1 and ET_BR in portal veins of male rats but did not alter gene
236 expression of ET_AR (18). In humans, low testosterone concentration was associated with higher
237 plasma ET-1 in healthy adults (14) and patients with coronary artery disease (1). Ours is the first
238 study to examine the relation between testosterone concentration and ET_BR protein expression
239 in men, however we did not observe a significant correlation between these two variables.
240 Furthermore, ET_BR protein expression in men with high and low T was not different (0.37 ± 0.14
241 vs. 0.42 ± 0.20 AU; $P=0.63$), further supporting preserved receptor expression regardless of
242 testosterone concentration. Future studies are needed to determine if cellular expression of ET-
243 1 is altered by testosterone in men, and whether there is a relation between free testosterone
244 concentration and cellular changes in ET_BR and ET-1.

245 Traditional cardiometabolic risk factors also change with aging. Although our sample
246 was free of overt disease, we did observe expected age-related increase in total cholesterol,
247 LDL cholesterol, and fasting plasma glucose. In our previous study in young and
248 postmenopausal women (8), these age-related changes were also noted, but we reported a
249 significant inverse correlation between ET_BR and LDL cholesterol in women (8). Thus,
250 endothelial ET_BR may be atheroprotective in women (13). Interestingly, we did not observe a
251 significant correlation between these variables in men in the current study, but did see a
252 significant inverse correlation between ET_BR protein expression and fasting plasma glucose.
253 Emerging evidence suggests that the ET_BR on vascular smooth muscle cells are upregulated in
254 response to high glucose concentrations and improve insulin sensitivity (10, 17), but whether
255 there is a role for endothelial ET_BR regulating glucose remains unknown.

256 *Limitations:* We recognize limitations with our study. First, we assessed ET_BR protein
257 expression in venous cells as opposed to arterial cells. However, previous studies have

258 demonstrated a strong correlation in protein expression of various markers related to endothelial
259 health between venous and arterial cells (20). Protein expression of various markers from
260 venous endothelial cells often correlate with functional outcomes of vascular health such as
261 FMD (3, 5, 7, 8). Thus, venous cells are a useful surrogate (20) and pose less risk to
262 participants. Second, we assessed ET_BR on endothelial cells, but they are also located on
263 vascular smooth muscle cells along with ET_AR. The balance between ET_BR on endothelial cells
264 vs smooth muscle cells could elicit important function changes (i.e., vasoconstriction), and the
265 ratio of ET_BR and ET_AR may be critical in understanding age and sex differences in vascular
266 health.

267 In conclusion, we show that aging does not alter endothelial cell ET_BR protein
268 expression in men. These findings are in contrast to previous data in women (8), and further
269 support sex differences in the endothelin system. Understanding which mechanisms do and do
270 not contribute to endothelial function are crucial for developing strategies to prevent or offset the
271 development of cardiovascular disease with aging.

272

273

274

275

276 **Acknowledgements**

277 We wish to thank our research nurses Carolyn Haines and Wendy Nichols with their assistance
278 in collecting endothelial cells as well as Josh Hobson and Katherine Masso for recruiting
279 participants. We are grateful to our participants for their time.

280

281 **Grants**

282 This research was supported by National Institutes of Health (NIH R01 HL 146558) to MMW,
283 and the Center of Biomedical Research Excellence in Cardiovascular Health (P20 GM113125)
284 to DGE.

285

286 **Disclosures**

287 MMW is a paid consultant for Orchestra BioMed.

288

289 **Author contributions**

290 ST, ADV, AVK, AS, and MMW performed the experiments; ST, AVD, AS, and MMW analyzed
291 the data; ST, AVK, AS, ADV, DGE and MMW interpreted the results of the experiments; ST,
292 ADV, and MMW prepared the figures; AVK, DGE and MMW conceived and designed the study;
293 ST and MMW drafted the manuscript; all authors critically revised and approved the final
294 manuscript.

295

296

297 **Figure Legends:**

298

299 **Figure 1:** (A) Flow-mediated dilation (%) is lower in older men (OM, n=13) compared to young
300 men (YM, n=14). (B) Endothelial-B receptor (ET_BR) protein expression expressed as arbitrary
301 units (AU) in venous endothelial cells collected from 15 YM and 12 OM along with
302 representative images of venous ETBR protein expression from one YM and one OM. Unpaired
303 t-tests were used to determine differences between groups (panels A & B). (C) Pearson
304 correlation showing trend towards inverse relation between flow-mediated dilation percent
305 change (FMD %) and endothelin-B receptor (ET_BR) protein expression (in arbitrary units, AU), in
306 young men (n=13, Closed circles) and older men (n=11, open circles).

307

308 **Figure 2:** Endothelial-B receptor (ET_BR) protein expression expressed as arbitrary units (AU) in
309 venous endothelial cells collected in young and older men (current study) compared to young
310 women (YW) and postmenopausal women (PMW) from our prior publication (redrawn from (8)).
311 Expression of ET_BR is higher in YW compared to PMW (P=0.02), and also higher in YW
312 compared to YM.

313 * P < 0.05.

314

315

316

317

318 **References:**

- 319 1. **Akseh S, Karimi MA, Safaie N, Valizadeh A, Rahmanpour D, Pezeshkian M, Nouri**
320 **M, Faridvand Y, and Jodati A.** The serum levels of testosterone in coronary artery disease
321 patients; relation to NO, eNOS, endothelin-1, and disease severity. *Horm Mol Biol Clin Investig*
322 43: 55-61, 2021.
- 323 2. **Babcock MC, DuBose LE, Witten TL, Stauffer BL, Hildreth KL, Schwartz RS, Kohrt**
324 **WM, and Moreau KL.** Oxidative Stress and Inflammation Are Associated With Age-Related
325 Endothelial Dysfunction in Men With Low Testosterone. *J Clin Endocrinol Metab* 107: e500-
326 e514, 2022.
- 327 3. **Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, and Seals DR.**
328 Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase.
329 *Am J Physiol Heart Circ Physiol* 297: H425-432, 2009.
- 330 4. **Ergul A, Shoemaker K, Puett D, and Tackett RL.** Gender differences in the expression
331 of endothelin receptors in human saphenous veins in vitro. *J Pharmacol Exp Ther* 285: 511-517,
332 1998.
- 333 5. **Gavin KM, Seals DR, Silver AE, and Moreau KL.** Vascular endothelial estrogen
334 receptor alpha is modulated by estrogen status and related to endothelial function and
335 endothelial nitric oxide synthase in healthy women. *J Clin Endocrinol Metab* 94: 3513-3520,
336 2009.
- 337 6. **Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T,**
338 **Ozaki S, Nagase T, and et al.** Biochemical and pharmacological profile of a potent and
339 selective endothelin B-receptor antagonist, BQ-788. *Proc Natl Acad Sci U S A* 91: 4892-4896,
340 1994.
- 341 7. **Jablonski KL, Chonchol M, Pierce GL, Walker AE, and Seals DR.** 25-Hydroxyvitamin
342 D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-
343 aged and older adults. *Hypertension* 57: 63-69, 2011.
- 344 8. **Kuczmarski AV, Shoemaker LN, Hobson JC, Edwards DG, and Wenner MM.** Altered
345 endothelial ETB receptor expression in postmenopausal women. *Am J Physiol Heart Circ*
346 *Physiol* 319: H242-H247, 2020.
- 347 9. **Lin HY, Kaji EH, Winkel GK, Ives HE, and Lodish HF.** Cloning and functional
348 expression of a vascular smooth muscle endothelin 1 receptor. *Proc Natl Acad Sci U S A* 88:
349 3185-3189, 1991.
- 350 10. **Lin Y, Zhao Y, and Liu E.** High glucose upregulates endothelin type B receptors in
351 vascular smooth muscle cells via the downregulation of Sirt1. *Int J Mol Med* 41: 439-445, 2018.

- 352 11. **Martin BJ, and Anderson TJ.** Risk prediction in cardiovascular disease: the prognostic
353 significance of endothelial dysfunction. *Can J Cardiol* 25 Suppl A: 15A-20A, 2009.
- 354 12. **Miyauchi T, Yanagisawa M, Iida K, Ajisaka R, Suzuki N, Fujino M, Goto K, Masaki**
355 **T, and Sugishita Y.** Age- and sex-related variation of plasma endothelin-1 concentration in
356 normal and hypertensive subjects. *Am Heart J* 123: 1092-1093, 1992.
- 357 13. **Muller G, Catar RA, Niemann B, Barton M, Knels L, Wendel M, and Morawietz H.**
358 Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins.
359 *Exp Biol Med (Maywood)* 231: 766-771, 2006.
- 360 14. **Pastuszak AW, Kohn TP, Estis J, and Lipshultz LI.** Low Plasma Testosterone Is
361 Associated With Elevated Cardiovascular Disease Biomarkers. *J Sex Med* 14: 1095-1103,
362 2017.
- 363 15. **Pearson LJ, Yandle TG, Nicholls MG, and Evans JJ.** Regulation of endothelin-1
364 release from human endothelial cells by sex steroids and angiotensin-II. *Peptides* 29: 1057-
365 1061, 2008.
- 366 16. **Ramick MG, Brian MS, Matthews EL, Patik JC, Seals DR, Lennon SL, Farquhar WB,**
367 **and Edwards DG.** Apocynin and Tempol ameliorate dietary sodium-induced declines in
368 cutaneous microvascular function in salt-resistant humans. *Am J Physiol Heart Circ Physiol* 317:
369 H97-H103, 2019.
- 370 17. **Rivera-Gonzalez OJ, Kasztan M, Johnston JG, Hyndman KA, and Speed JS.** Loss
371 of endothelin type B receptor function improves insulin sensitivity in rats. *Can J Physiol*
372 *Pharmacol* 98: 604-610, 2020.
- 373 18. **Rosignoli Pde S, De Labio RW, Payao SL, Pereira OC, and Chies AB.**
374 Orchidectomy enhances the expression of endothelin-1 and ETB receptors in rat portal vein. *J*
375 *Smooth Muscle Res* 50: 85-92, 2014.
- 376 19. **Seals DR, Jablonski KL, and Donato AJ.** Aging and vascular endothelial function in
377 humans. *Clin Sci (Lond)* 120: 357-375, 2011.
- 378 20. **Silver AE, Christou DD, Donato AJ, Beske SD, Moreau KL, Magerko KA, and Seals**
379 **DR.** Protein expression in vascular endothelial cells obtained from human peripheral arteries
380 and veins. *J Vasc Res* 47: 1-8, 2010.
- 381 21. **Stanhewicz AE, Wenner MM, and Stachenfeld NS.** Sex differences in endothelial
382 function important to vascular health and overall cardiovascular disease risk across the lifespan.
383 *Am J Physiol Heart Circ Physiol* 315: H1569-H1588, 2018.

- 384 22. **Stauffer BL, Westby CM, Greiner JJ, Van Guilder GP, and Desouza CA.** Sex
385 differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults. *Am J*
386 *Physiol Regul Integr Comp Physiol* 298: R261-265, 2010.
- 387 23. **Teoh H, Quan A, Leung SW, and Man RY.** Differential effects of 17beta-estradiol and
388 testosterone on the contractile responses of porcine coronary arteries. *Br J Pharmacol* 129:
389 1301-1308, 2000.
- 390 24. **Thijssen DHJ, Bruno RM, van Mil A, Holder SM, Fatta F, Greyling A, Zock PL,**
391 **Taddei S, Deanfield JE, Luscher T, Green DJ, and Ghiadoni L.** Expert consensus and
392 evidence-based recommendations for the assessment of flow-mediated dilation in humans. *Eur*
393 *Heart J* 40: 2534-2547, 2019.
- 394 25. **Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-**
395 **Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV,**
396 **Evenson KR, Eze-Nliam C, Fugate S, Generoso G, Heard DG, Hiremath S, Ho JE, Kalani R,**
397 **Kazi DS, Ko D, Levine DA, Liu J, Ma J, Magnani JW, Michos ED, Mussolino ME,**
398 **Navaneethan SD, Parikh NI, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge MP,**
399 **Thacker EL, Virani SS, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Martin SS,**
400 **American Heart Association Council on E, Prevention Statistics C, and Stroke Statistics**
401 **S.** Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart
402 Association. *Circulation* 147: e93-e621, 2023.
- 403 26. **Van Guilder GP, Westby CM, Greiner JJ, Stauffer BL, and DeSouza CA.** Endothelin-
404 1 vasoconstrictor tone increases with age in healthy men but can be reduced by regular aerobic
405 exercise. *Hypertension* 50: 403-409, 2007.
- 406 27. **Westby CM, Weil BR, Greiner JJ, Stauffer BL, and DeSouza CA.** Endothelin-1
407 vasoconstriction and the age-related decline in endothelium-dependent vasodilatation in men.
408 *Clin Sci (Lond)* 120: 485-491, 2011.
409

Figure 1A




Figure 1B




Figure 1C




Figure 2




Table 1. Participant characteristics.

	YM (n = 17)	OM (n = 14)
Age, yrs	24 ± 5	60 ± 6 *
BMI, kg/m ²	24 ± 2	26 ± 3
Body mass (kg)	79 ± 11	81 ± 11
Height (cm)	181 ± 6	177 ± 7
SBP, mmHg	122 ± 10	123 ± 11
DBP, mmHg	70 ± 6	77 ± 7 *
Total Cholesterol, mg/dL	133 ± 31	210 ± 34 *
HDL, mg/dL	46 ± 5	56 ± 14 *
LDL, mg/dL	73 ± 29	131 ± 28 *
Glucose, mg/dL	84 ± 5	94 ± 8 *
Total Testosterone, mg/dL	9.10 ± 2.68	6.28 ± 4.21 *

Values are mean±SD. YM, young men; OM, older men; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Total Cholesterol, HDL, LDL, and Glucose were obtained in 8YM and 13 OM. Total testosterone was measured in 17 YM and 13 OM. Groups were compared using unpaired t-tests. * $P < 0.05$ vs. YM.